九洲药业
(603456)
| 流通市值：152.18亿 | | | 总市值：152.18亿 |
| 流通股本：8.82亿 | | | 总股本：8.82亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,575,246,576.12 | 1,200,661,700.09 | 5,508,595,171.33 | 4,160,487,725.65 |
| 营业收入 | 2,575,246,576.12 | 1,200,661,700.09 | 5,508,595,171.33 | 4,160,487,725.65 |
| 二、营业总成本 | 2,064,924,507.55 | 977,467,580.38 | 4,293,596,413.64 | 3,195,334,808.19 |
| 营业成本 | 1,625,176,975.78 | 763,953,073.5 | 3,478,574,735.98 | 2,598,161,194.94 |
| 税金及附加 | 33,247,353.02 | 17,852,373.97 | 73,010,518.7 | 56,418,015.52 |
| 销售费用 | 60,228,032.94 | 28,718,357.83 | 107,677,996.07 | 76,615,206.8 |
| 管理费用 | 200,426,264.76 | 103,180,596.61 | 393,892,861.08 | 287,210,556.75 |
| 研发费用 | 129,591,818.45 | 56,238,005.87 | 256,985,924.21 | 194,755,936.65 |
| 财务费用 | 16,254,062.6 | 7,525,172.6 | -16,545,622.4 | -17,826,102.47 |
| 其中:利息费用 | 2,475,787.12 | 1,353,703.8 | 10,124,312.57 | 5,779,648.27 |
| 其中:利息收入 | 12,925,371.41 | 6,096,023.26 | 41,316,673.88 | 33,434,990.25 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 10,161,121.37 | 5,061,216.96 | 3,555,802.23 | -2,938,045.57 |
| 资产处置收益 | -2,795,632.28 | -834,740.04 | -5,159,651.38 | -3,928,629.58 |
| 资产减值损失(新) | -37,944,608.09 | -13,621,086.35 | -337,761,490.03 | -90,619,499.16 |
| 信用减值损失(新) | -7,523,210.97 | -3,516,604.08 | 14,504,746.6 | 20,837,557.46 |
| 其他收益 | 14,989,373.65 | 9,555,579.87 | 34,807,092.33 | 23,846,745.27 |
| 四、营业利润 | 487,209,112.25 | 219,838,486.07 | 924,945,257.44 | 912,351,045.88 |
| 加:营业外收入 | 767,282.86 | 141,674.93 | 1,626,062.06 | 2,613,928 |
| 减:营业外支出 | 2,545,938.38 | 122,293.54 | 7,119,920.98 | 5,157,578.23 |
| 五、利润总额 | 485,430,456.73 | 219,857,867.46 | 919,451,398.52 | 909,807,395.65 |
| 减:所得税费用 | 104,736,434.1 | 51,586,944.26 | 190,908,281.04 | 161,133,051.61 |
| 六、净利润 | 380,694,022.63 | 168,270,923.2 | 728,543,117.48 | 748,674,344.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 380,694,022.63 | 168,270,923.2 | 728,543,117.48 | 748,674,344.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 387,393,043.36 | 172,084,196.97 | 730,073,370.43 | 747,652,814.09 |
| 少数股东损益 | -6,699,020.73 | -3,813,273.77 | -1,530,252.95 | 1,021,529.95 |
| 扣除非经常损益后的净利润 | 386,203,630.18 | 168,770,734.87 | 729,026,847.84 | 745,937,192.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.44 | 0.19 | 0.82 | 0.84 |
| (二)稀释每股收益 | 0.44 | 0.19 | 0.82 | 0.84 |
| 八、其他综合收益 | -17,745,125.97 | -8,776,591.02 | -1,972,075.01 | 3,761,640.59 |
| 归属于母公司股东的其他综合收益 | -17,745,125.97 | -8,776,591.02 | -1,972,075.01 | 3,761,640.59 |
| 九、综合收益总额 | 362,948,896.66 | 159,494,332.18 | 726,571,042.47 | 752,435,984.63 |
| 归属于母公司股东的综合收益总额 | 369,647,917.39 | 163,307,605.95 | 728,101,295.42 | 751,414,454.68 |
| 归属于少数股东的综合收益总额 | -6,699,020.73 | -3,813,273.77 | -1,530,252.95 | 1,021,529.95 |
| 公告日期 | 2026-08-04 | 2026-04-24 | 2026-04-24 | 2025-10-16 |
| 审计意见(境内) | | | 标准无保留意见 | |